Barclays analyst Balaji Prasad raised the firm’s price target on Ligand (LGND) to $125 from $110 and keeps an Overweight rating on the shares as part of a Q3 preview for the specialty pharmaceuticals.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LGND: